The world had been anticipating another influenza pandemic since the last one in 1968. The
pandemic influenza A H1N1 2009 virus (A/2009/H1N1) finally arrived, causing the first …

Annually, influenza virus infects millions of people worldwide. Vaccination programs against
seasonal influenza infections require the production of hundreds of million doses within a …

The non-structural protein 1 of influenza virus (NS1) is a relatively small polypeptide with an
outstanding number of ascribed functions. NS1 is the main viral antagonist of the innate …

Most viruses express one or several proteins that counter the antiviral defences of the host
cell. This is the task of non-structural protein NS1 in influenza viruses. Absent in the viral …

Influenza A viruses (IAV) can infect a broad range of animal hosts, including humans. In
humans, IAV causes seasonal annual epidemics and occasional pandemics, representing a …

In contrast to influenza A viruses, which have been investigated extensively, influenza B
viruses have attracted relatively little attention. However, influenza B viruses are an …

Influenza A virus is a significant cause of morbidity and mortality worldwide. Severe
influenza is recognized as a clinical syndrome, characterized by hyperinduction of …

Abstract Nonstructural protein 1 (NS1) of influenza A virus plays a central role in virus
replication and blockade of the host innate immune response, and is therefore being …

The only licensed live attenuated influenza A virus vaccines (LAIVs) in the United States
(FluMist) are created using internal protein-coding gene segments from the cold-adapted …

Influenza A and B infections are a worldwide health concern to both humans and animals.
High genetic evolution rates of the influenza virus allow the constant emergence of new …